



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار




MONA MAGHRABY



Faculty of science

Microbiology department



Management of some opportunistic microbial pathogens isolated from cancer patients using fungal nanoparticles.

Thesis

Submitted for Degree of Doctor Philosophy of Science (Microbiology)

By

Mohammed Kasem Mohammed Ali Lila

M.Sc. in Microbiology (2016)

Supervisors

Dr. Yousseria Mohamed Hassen Shetaia

Professor of Mycology

Head of Microbiology department

Faculty of Science- Ain-Shams University

Dr. Gamal Mohammed El-Saied El- Sherbiny

Professor of Medical Microbiology

Botany and Microbiology department

Faculty of science- Al-Azhar University

Dr. Samar Samir Mohamed Elsayed

Assistant professor of Microbiology

Department of Microbiology

Faculty of Science- Ain-Shams University

Dr. Marwa Mohammed Fathy Elswify

Lecturer of clinical pathology

National cancer Institute

Cairo University

Microbiology Department

Faculty of science

Ain shams University

2021

Approval sheet

**Management of some opportunistic microbial pathogens isolated from cancer patients
using fungal nanoparticles.**

By

Mohamed Kasem Mohamed Ali Lila

M.Sc. in Microbiology (2016)

Supervisors

Approved

Prof. Dr. Yousseria Mohamed Hassen Shetaia.

.....

Professor of Microbiology (Mycology) and head of Microbiology department -Faculty of Science,
Ain-Shams University

Prof. Dr. Gamal Mohammed El-Saied El-Sherbiny.

.....

Professor of medical Microbiology, Botany and Microbiology department, Faculty of science.
Al-Azhar University

Dr. Samar Samir Mohamed Elsayed

.....

Assistant professor of Microbiology, Department of Microbiology, Faculty of Science,
Ain-Shams University

Dr. Marwa Mohammed Fathy Elswify

.....

Lecturer of clinical pathology. National cancer Institute, Cairo University

Examiner committee

Approved

Prof. Dr. Efreem Mohamed Khalifa el-tonsiy

.....

Professor of pediatrics, faculty of medicine El-Azhar University (Boys)

Prof. Dr. Eman Fathy Abdelhamid Sharaf

.....

Professor of Microbiology, faculty of science, Cairo University, Cairo

Prof. Dr. Yousseria Mohamed Hassen Shetaia

.....

Professor of Microbiology (Mycology) and head of Microbiology department, Faculty of Science,
Ain-Shams University,

Prof. Dr. Gamal Mohammed El-Saied El-Sherbiny

.....

Professor of medical Microbiology, Botany and Microbiology department, Faculty of science.
Al-Azhar University.

Date of examination/...../2021

Approval date/...../2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَلَقَدْ آتَيْنَا دَاوُودَ وَسُلَيْمَانَ عِلْمًا وَقَالَا الْحَمْدُ لِلَّهِ الَّذِي فَضَّلَنَا عَلَى كَثِيرٍ مِّنْ
عِبَادِهِ الْمُؤْمِنِينَ وَوَرِثَ سُلَيْمَانُ دَاوُودَ

[النمل: 15-16].

عن أبي الدرداء قال: سمعت رسول الله صلى الله عليه وسلم يقول :

(من سلك طريقاً يطلب فيه علماً؛ سلك الله به طريقاً من طرق الجنة،
والملائكة تضع أجنحتها رضا لطالب العلم، وإن العالم يستغفر له من في
السموات، ومن في الأرض، والحيتان في الماء، وفضل العالم على العابد
كفضل القمر ليلة البدر على سائر الكواكب، إن العلماء ورثة الأنبياء، إن
الأنبياء لم يورثوا ديناراً ولا درهماً، وأورثوا العلم، فمن أخذه؛ أخذ بحظ
وافر.

Acknowledgements

In the name of Allah, the Merciful, the beneficent, praise be to the lord of all worlds. Prayers and peace be upon our Prophet, Mohammad, his family and all of his companion. Praise be to God for the countless grace and provision, praise be to God for success and charity, praise be to God that provided me to my wonderful supervisors who helped me to complete this work. It is a pleasure to express my sincere thanks and appreciation to: **Prof. Dr. Yousseria Mohamed Hassen Shetaia**, Professor of Microbiology and head of Microbiology department Faculty of Science, Ain-Shams University and **Prof. Dr. Gamal Mohammed El-Saied El-Sherbiny**, Professor of medical Microbiology, Botany and Microbiology Department, Faculty of science. Al-Azhar University, who have been a source of inspiration and guidance to me throughout my dissertation. their careful corrections during regular meetings and discussions always ensured a more thoughtful approach towards problem-solving. deep thanks are conveyed to **Dr. Samar Samir Mohamed Elsayed** Assistant professor of Microbiology. Department of Microbiology, Faculty of Science, Ain-Shams University and **Dr. Marwa Mohammed Fathy Elswify** Lecturer of clinical pathology. national cancer Institute, Cairo University for suggesting the subject of this thesis and for their constant supervision and encouragement throughout the work. Sincere thanks to the head and members of microbiology department, faculty of science, Ain shams university and Botany and microbiology department, al-Azhar university, Cairo, Egypt, for providing necessary laboratory facilities to execute this studies, I would like to thank my family for their moral support. special thanks to my wife for her support, help and encouragement. I am grateful to everyone who has helped and encouraged me.

I thank you all
Mohamed Kassem Mohamed Ali

Declaration

I declare the thesis entitled “Management of some opportunistic microbial pathogens isolated from cancer patients using fungal nanoparticles” has been composed solely by myself, and it has not been submitted, in whole or in part, in any previous application for a degree.

Tables of contents

No.	subject	page no.
	List of tables	I
	List of figures	v
	Abbreviations	viii
	Abstract	1
	Introduction	3
	Aim of the work	8
	Part I: literature review	
1.1	Immunocompromised patients and bacterial infection	12
1.1.1	<i>Escherichia coli</i>	12
1.1.2	<i>Klebsiella pneumoniae</i>	14
1.1.3	<i>Acinetobacter sp.</i>	15
1.1.4	<i>Pseudomonas sp.</i>	16
1.1.5	<i>Enterobacter sp.</i>	17
1.1.6	<i>Pantoea sp</i>	18
1.1.7	<i>Serratia</i>	18
1.1.8	<i>Burkholderia cepacia</i>	19
1.1.9	<i>Cedecea davisae</i>	20
1.1.10	<i>Citrobacter sp.</i>	21
1.1.11	<i>Proteus mirabilis</i>	21
1.1.12	<i>Staphylococcus aureus</i>	22
1.2	Immunocompromised patients and fungal infection	23
1.3	Antibiotics	27
1.3.1	Antibacterial classification	27
1.3.2	Antibacterial that inhibit cell wall synthesis	27
1.3.3	Antibacterial agents that breakdown cell membrane structure	28
1.3.4	Antibacterial agents that inhibit the structure and	29

No.	subject	page no.
	function of nucleic acid.	
1.3.5	Antibacterial agents that inhibit the protein synthesis	30
1.3.6	Antibiotics Block key metabolic pathway	31
1.4	Antimicrobial resistance	31
1.4.1	Immunocompromised patients and resistant bacterial isolates.	32
1.4.2	Methods to solve the crisis of antibiotic resistance	33
1.5	Preparation of nanoparticles	34
1.5.1	Biogenic synthesis of nanoparticles	36
1.5.2	Biosynthesis of silver nanoparticles by fungi	38
1.5.3	Application of nanoparticles	40
1.5.4	Antimicrobial activity of nanoparticles	42
1.5.5	Factors affecting on antimicrobial activity of nanoparticles	44
1.5.6	Mechanism of antimicrobial activity of nanoparticles	46
1.5.7	Antimicrobial activity of silver nanoparticles	48
1.6	Amino acids enhance the activity of antibiotics.	51
	Part II: materials and methods	
2	Materials	53
2.1.1	Blood Agar Base Medium	53
2.1.2	MacConkey Agar Medium.	53
2.1.3	Sabouraud Dextrose agar	54
2.1.4	Chrom agar for <i>Candida</i> (Odds and Bernaerts 1994)	55
2.1.5	Muller-Hinton Agar (Mueller and Hinton, 1941)	56
2.1.6	Materials used for antibiotic susceptibility test.	56
2.1.7	Antibiotic discs used for antimicrobial susceptibility testing	56
2.2	Methods	57
2.2.1	Samples collection	57

No.	subject	page no.
2.2.2	isolation and purification of microbial isolates.	57
2.2.3	Identification of microbial isolates.	58
2.2.3.1	Morphological Studies	58
2.2.4	Identification of candida isolates	58
2.2.4.1	Chromogenic media	58
2.2.5	Automated Identification by Using the Biomerieux Vitek 2 System	59
2.3	Suspension Preparation	60
2.3.1	Inoculation.	61
2.3.2	Card Sealing and Incubation	61
2.3.3	Optical System	62
2.3.4	Test Reactions	62
2.3.5	Database Development	62
2.3.6	Analytical Techniques	63
2.3.7	Identification Levels	63
2.4	Antibiotic susceptibility of microbial isolates	64
2.4.1	Antibiotic susceptibility of bacterial isolates	64
2.4.2	Antibiotic susceptibility of candida isolates	67
2.4.3	Detection of extended-spectrum β -lactamase (ES β L) producing Gram- negative bacteria	68
2.5	Biosynthesis of Silver Nanoparticles	69
2.5.1	Characterization of the Biosynthesized Silver Nanoparticles	70
2.5.1.1	UV-visible spectroscopy	70
2.5.1.2	X-Ray Diffraction (XRD)	70
2.5.1.3	Transmission Electron Microscopy (TEM)	70
2.5.2	Antimicrobial activity of Biosynthesized Silver Nanoparticles	70

No.	subject	page no.
2.5.3	Cytotoxicity of Silver Nanoparticles	71
2.6	D-Amino acids enhance antimicrobials activity	72
	Part III: Results	
3.1	Sample's collection and microbial isolation	73
3.2	Identification of bacterial isolates	79
3.2.1	Characterization and identification of <i>E.coli</i>	79
3.2.2	Characterization and identification of <i>Klebsiella pneumoniae</i>	80
3.2.3	Characterization and identification of <i>Acinetobacter baumannii</i>	81
3.2.4	Characterization and identification of <i>Pseudomonas aeruginosa</i> Isolates	83
3.2. 5	Characterization and identification of <i>Enterobacter</i> sp. Isolates	84
3.2.6	Characterization and identification of <i>Proteus mirabilis</i> isolates	85
3.2.7	Characterization and identification of <i>Citrobacter freundii</i> isolates	86
3.2.8	Characterization and identification of <i>Pantoea agglomerans</i> isolates	87
3.2.9	Characterization and identification of <i>Serratia marcescens</i> isolates	88
3.2.10	Characterization and identification of <i>Cedecea advisae</i> isolate	89
3.2.11	Characterization and identification of <i>Burkholderia cepacia</i> isolate	90
3.2.12	Characterization and identification of <i>Staphylococcus aureus</i> isolates	91
3.2.13	Characterization and identification of <i>Staphylococcus</i>	92

No.	subject	page no.
	<i>haemolyticus</i> isolates	
3.2.14	Characterization and identification of <i>Staphylococcus epidermidis</i> isolates	93
3.3	Identification of <i>Candida</i> isolates using chromogenic agar	94
3.4	In vitro susceptibility of bacterial isolates to antibiotic	97
3.4.1	Susceptibility of <i>E. coli</i>	97
3.4.2	Susceptibility of <i>Klebsiella pneumonia</i>	99
3.4.3	Susceptibility of <i>Acinetobacter baumannii</i>	100
3.4.4	Susceptibility of <i>Pseudomonas aeruginosa</i> .	102
3.4.5	Susceptibility of <i>Enterobacter</i> sp.	103
3.4.6	Susceptibility of <i>Proteus mirabilis</i>	105
3.4.7	Susceptibility of <i>Citrobacter freundii</i>	106
3.4.8	Susceptibility of <i>Serratia marcescens</i>	108
3.4.9	Susceptibility of <i>Cedecea davisae</i>	109
3.4.10	Susceptibility of <i>Burkholderia cepacian</i>	111
3.4.11	Susceptibility of <i>Pantoea agglomerans</i>	112
3.4.12	Susceptibility of total Gram -negative bacteria	114
3.4.13	Susceptibility of <i>Staphylococcus</i> sp.	115
3.5	Detection of extended-spectrum β -lactamase (ES β L) producing Gram-negative bacteria	117
3.6	In-vitro susceptibility of <i>Candida</i> sp. to different antifungal	118
3.6.1	Susceptibility of <i>Candida albicans</i>	118
3.6.2	Susceptibility of <i>Candida tropicalis</i>	119
3.6.3	Susceptibility of <i>Candida glabrata</i>	120
3.6.4	Susceptibility of <i>Candida krusei</i>	121
3.6.5	Susceptibility of all <i>Candida</i> sp.	123
3.7	Biosynthesis of silver nanoparticles	124

No.	subject	page no.
3.7.1	Assessment of Antimicrobial activity of the biosynthesized silver Nanoparticles	127
3.8	Assessment of Cytotoxic activity of biosynthesized AgNPs	128
3.9	Assessment the role of amino acids in enhancement of antimicrobial activity against resistant microbes isolated from clinical samples of cancer patient	129

Part IV: Discussion and conclusion

Discussion	132
Conclusion	152
Recommendations	153
Summary	154
References	157
Arabic summary (الملخص العربي)	

List of tables

No.	Subject	page no.
Table (1):	Suspension turbidities used for card inoculation.	60
Table (2):	Identification levels of Vitek 2.	63
Table (3):	Standard inhibition zone diameter in the protocol chart of bacterial isolates, sensitive, intermediate or resistance according to CLSI, 2018.	66
Table (4):	Standard inhibition zone diameter in the protocol chart of candida isolates, sensitive, intermediate or resistance according to NCCLS 2008, Rosco Diagnostic Company (Neosensitabs, Denmark). and CLSI, 2018.	68
Table (5)	Percentage of occurrence of the collected samples.	74
Table (6):	Bacterial species isolated from different clinical samples collected from cancer patients.	75
Table (7):	<i>Candida</i> species isolated from different clinical samples in cancer patients.	76
Table (8):	Characterization of <i>Escherichia coli</i> isolates using the VITEK2 system.	80
Table (9):	Characterization of <i>Klebsiella pneumoniae</i> isolates using VITEK2 system.	81
Table (10):	Characterization of <i>Acinetobacter baumannii</i> isolates using VITEK2 system.	82
Table (11):	Characterization of <i>Pseudomonas aeruginosa</i> isolates using VITEK2 system.	83
Table (12):	Characterization of <i>Enterobacter</i> sp. isolate using VITEK2 System.	84
Table (13):	Characterization of <i>Proteus mirabilis</i> isolate using VITEK2 system.	85
Table (14):	Characterization of <i>Citrobacter freundii</i> isolates using VITEK2 system.	86
Table (15):	Characterization of <i>Pantoea agglomerans</i> isolate using VITEK2 system.	87
Table (16):	Characterization of <i>Serratia marcescens</i> isolate using VITEK2 system.	88